Navigation Links
Catabasis Names Ian Sanderson Chief Financial Officer
Date:11/13/2013

CAMBRIDGE, Mass., Nov. 13, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced that it has named Ian Sanderson its chief financial officer. Mr. Sanderson brings to Catabasis more than 25 years of experience in life sciences investment research and financial operations.

Prior to joining Catabasis, Mr. Sanderson was a senior adviser at JSB-Partners, L.P., a global life sciences advisory firm specializing in strategic partnering and M&A transactions. Prior to JSB-Partners, Mr. Sanderson was a managing director at Cowen and Company, LLC, where he spent 20 years as an equity research analyst covering the specialty pharmaceuticals, pharmaceuticals and medical technology sectors. Mr. Sanderson began his life sciences career in healthcare investment banking at Cowen and Company and at Houlihan Lokey Howard and Zukin, and in financial operations at U.S. Surgical Corporation (now Covidien). Mr. Sanderson also served as a director of development-stage, drug delivery technology company Spherics, Inc., advising on strategic and product development.

"Ian's decades of experience as an advisor and financial analyst and his extensive network of relationships in the life sciences financial community make him an excellent addition to the Catabasis team as the company progresses toward important milestones such as top-line Phase 2 data for our lead compound, CAT-2003," said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis.

Mr. Sanderson holds a bachelor's degree in political economics from Williams College and an MBA in finance from the University of Pennsylvania.

About CatabasisCatabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.

Please visit www.catabasis.com for more information.Media ContactsCorporate ContactTony Russo, Ph.D.Amy LynchMatt Middleman, M.D.Catabasis Pharmaceuticals, Inc.Russo PartnersT: (617)-349-1971T: 212-845-425alynch@catabasis.comT: 212-845-4272tony.russo@russopartnersllc.commatt.middleman@russopartnersllc.com
'/>"/>

SOURCE Catabasis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Catabasis Pharmaceuticals Announces Issuance of Patents for CAT-1000 and CAT-2000 Series
2. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
3. Imprimis Pharmaceutical Names Seasoned Ophthalmology Executive John Saharek as Vice-President of Commercialization for its Ophthalmology Division
4. Accelerate Diagnostics, Inc. Names Mark C. Miller to Board of Directors
5. 2013 ISPE Facility of the Year Awards Program Names Novartiss United States Flu Cell Culture Facility as Overall Winner
6. Pharmacy Technician Certification Board Names Linda Henson and Rico Powell as 2013 PTCB CPhT of the Year Finalists
7. Pharmacy Technician Certification Board Names Master Sergeant Jessica Hughes the 2013 PTCB CPhT of the Year
8. Aratana Therapeutics names Wendy Yarno to its Board of Directors
9. CIVCO Names Darrell Newcombe as Vice President of International Sales for Radiation Oncology
10. Cyberonics Names Rohan J. Hoare, Ph.D. Senior Vice President, Strategic Planning
11. ImmusanT Names Ferdinand E. Massari as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Eli Lilly and ... the neoMONARCH study of abemaciclib, a cyclin-dependent kinase (CDK) ... of reducing expression of Ki67, a biomarker of cell ... the Phase 2 trial presented during the official press ... (SABCS) evaluated abemaciclib, both alone or in combination with ...
(Date:12/7/2016)... Global Cervical Dysplasia Market: Scope and ... dysplasia market analyzes the current and future prospects ... executive summary, including a market snapshot that provides ... The research is a combination of primary and ... our research efforts along with information collected from ...
(Date:12/7/2016)... REPORT OBJECTIVES The report ... intelligence on a market segment, based on geography. ... in the report. The primary objectives of this ... intelligence through detailed segmentation, 2) market size and ... developments, market situation, trends, 3) detailed analysis of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a family ... in and around the Hancock County area, is announcing the launch of a charity ... , The Hancock County Food Pantry has worked for more than 30 years to ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... to families and business owners in and around central Kansas, is joining the ... at-risk youth in the region. , Headquartered in Wichita, Youth Horizons works to ...
(Date:12/7/2016)... ... , ... Students attending Envision’s summer 2017 National Youth ... experience in an emergency medical simulation, When Care is Hours Away. This dynamic ... skills that are critical success in a future career and beyond. , The ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare ... The MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone ... when it’s needed. , A 2’ x 4’ model features four modes: ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is a simple, ... and tightening the skin of the face to create more youthful features. While ... very little downtime, Silhouette Instalift is a novel, minimally invasive facial procedure that ...
Breaking Medicine News(10 mins):